---
title: "Traws Climbs 20% On Hantavirus Drug Development Push"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285733546.md"
description: "Traws Pharma Inc. (TRAW) announced plans to advance clinical candidates for Hantavirus treatment, leading to a 20% rise in shares during pre-market trading. The company specializes in small-molecule antiviral drugs targeting negative-strand RNA viruses. Hantaviruses, transmitted by rodents, have high fatality rates and currently lack approved treatments. This announcement follows a recent outbreak on a cruise ship, prompting Traws to utilize its drug development assets to create an effective treatment. TRAW shares rose from $1.70 to $2.08, reflecting a 22.42% increase."
datetime: "2026-05-08T13:25:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285733546.md)
  - [en](https://longbridge.com/en/news/285733546.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285733546.md)
---

# Traws Climbs 20% On Hantavirus Drug Development Push

(RTTNews) - Traws Pharma Inc. (TRAW), a clinical-stage biopharmaceutical company, on Friday announced plans to advance potential clinical candidates for the treatment and prevention of Hantavirus infections.

Following the announcement, shares are up over 20% in the pre-market.

Traws specializes in the manufacture of small-molecule antiviral drugs targeting negative-strand RNA viruses, such as influenza, H5N1 bird flu, and SARS CoV-2. RNA viruses face obstacles in replicating their genomes during pathogenesis in eukaryotic cells, allowing for the small molecule antivirals to effectively target the viral bodies with high specificity and safety.

Hantaviruses are a group of negative-strand RNA viruses, commonly borne and transmitted by rodents. Transmission may occur from human to human, yet this is rarer. Fatality rates lie between 30% to 50%. Advanced cases can result in a severe respiratory disease called Hantaan pulmonary disease, which currently has no approved treatments.

The announcement from Traws comes after a recent Hantavirus breakout on a cruise ship, resulting in at least three reported deaths and several infected.

The company stated intentions to rapidly utilize its drug development and viral testing assets, and to access proprietary clinical libraries to design an effective drug against Hantavirus.

TRAW closed Thursday at $1.70. In the pre-market, shares are trading at $2.08, up 22.42%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [TRAW.US](https://longbridge.com/en/quote/TRAW.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [BioMarin's drug shows significant growth gains in children in late-stage trial](https://longbridge.com/en/news/287121584.md)
- [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)